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patient’s anatomy and the target volumes to be irradiated, 
and further individualized after balancing possible benefits 
and risks that can be anticipated based on the outcome of 
treatment planning. Therefore, in agreement with the 
“Pareto principle”, it is advisable to choose one basic 
treatment technique for the department that is most 
appropriate for 80% of the cases and select out of different 
other treatment setups in a highly individualized manner for 
the remaining 20% for which the basic treatment setup might 
not be optimal. 
In the meantime, our knowledge about breast cancer and its’ 
treatment continues to increase, leading to changing 
attitudes towards the selection of the most appropriate 
target volumes which might either be smaller like partial 
breast irradiation for low risk patients or quite more 
extended like comprehensive locoregional irradiation 
including the internal mammary lymph nodes for patients 
with adverse risk factors. At the same time, dose prescription 
will follow the outcome of prospective clinical trials with 
hypofractionation with daily doses below 3 Gy already widely 
introduced in daily clinical practice and with higher daily 
doses or dose variation over the target volumes depending on 
the risk of recurrences being investigated. This can only go 
hand in hand with a continuing improvement of treatment 
delivery with a more homogeneous dose distribution overall 
and if indicated an intended dose variation like in the 
simultaneous integrated boost technique for high risk 
volumes. For all of this, an optimal interdisciplinary 
collaboration between researchers, radiation oncologists, 
medical physicists and radiation therapists is obviously 
indispensable. 
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The aim of this lecture is to provide the practicing radiation 
oncologist with an overview of radiotherapy practice in the 
era of molecularly targeted agents, focusing on issues of 
safety and toxicity when these modalities are delivered 
concurrently or in interdigitated fashion.  
As more targeted agents are approved for the treatment of 
metastatic cancers, the challenge of managing these 
combinations in the palliative and oligometastatic settings, 
where the use of standard low- and SBRT dose range 
prescriptions are employed, respectively, is becoming 
increasingly common.  An overview of available clinical data 
will be provided for classes of agents in common use, 
including inhibitors of the EGFR, VEGF and mTOR axes.  
Immunomodulatory agents and PARP inhibitors will also be 
discussed. 
Design of clinical trials to evaluate combinations of targeted 
agents with radiotherapy also presents unique challenges. 
Issues regarding endpoint selection and DLT definition will be 
explored using data and illustrative examples.  Alternative 
approaches of capturing toxicity data, e.g. from population 
databases will also be discussed. 
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Quality assurance and commissioning of brachytherapy 
treatment planning systems (TPS) comprise among other 
tasks verification of single and multiple source isodose 
distributions, applicator reconstruction, electronic data 
transfer, optimization software and dose volume histogram 
calculations. Comparison of TPS derived plans against a 
second TPS is valuable as is end-to-end dose measurements 
of plan delivery. While output by dose calculation engines 
based on the TG43 formalism is easy to verify, the task is 
more complex for the recently introduced model based dose 
calculations algorithms (MBDCA). The American Association of 
Physicists in Medicine (AAPM) has initiated a “Working Group 
on Model-Based Dose Calculation Algorithms in 
Brachytherapy” to derive and distribute well defined test 
plans and recommendations for commissioning MBDCAs.  This 
lecture will cover existing recommendations for 
commissioning radiotherapy and in particular brachytherapy 
TPS, provide practical examples of the process and an update 
on the ongoing work to derive and distribute test plans for 
commissioning MBDCAs.  
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Purpose: Radiation induced pulmonary toxicity after radical 
radiotherapy or chemoradiation is difficult to score in lung 
cancer patients because tumor progression and exacerbation 
of preexisting pulmonary co-morbidities may have similar 
clinical characteristics. This presentation discusses several 
aspects of pulmonary toxicity. 
A mild dry cough is common during the acute phase of lung 
irradiation. Radiation Pneumonitis (RP) is characterized by 
dyspnea, unproductive cough and occasionally mild fever, 
and typically presents between 1-6 months after treatment. 
Severe late lung complications, like pulmonary fibrosis, 
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hemorrhage, bronchial- or mainstem stenosis are relatively 
unusual and may develop beyond 4 years after treatment.  
Estimation of the probability to develop RP is important for 
patients with inoperable lung cancer. Studies of the risk of 
RP have used various dosimetric parameters like the Mean 
Lung Dose (MLD) or V20. To increase the sensitivity to predict 
RP, dosimetric and non-dosimetric factors can be combined. 
Palma et al (ref 1) performed a meta-analysis of both 
dosimetric and non-dosimetric factors based on individual 
patients treated with concurrent chemoradiation. The factors 
predicting RP were type of chemotherapy 
(carboplatin/paclitaxel vs cisplatin/etoposide or other 
chemotherapy), age, MLD and V20. Pre-existing radiological 
interstitial lung disease (ILD) findings were analyzed in a 
recent Japanese study of 157 patients and correlated with 
the incidence of RP after stereotactic body radiation therapy 
(SBRT) for stage I NSCLC (ref 2). Multivariate analysis 
identified ILD as risk factor for ≥ Gr2 RP, as well as the 
irradiated lung volume. 
Recall radiation pneumonitis describes a rare reaction in 
previously irradiated lung tissue after application of 
triggering agents. Recall RP has been associated with 
multiple drugs such as taxanes, gemcitabine, vinca alkaloids, 
adriamycin and epirubicin. Tyrosine kinase inhibitors 
(erlotinib, cetuximab, sunitinib) have also been associated 
with recall RP and increased risk of severe RP following 
palliative or definitive radiation therapy. Some researchers 
have found a significant correlation between pulmonary 
toxicity and pre- and post radiation therapy pulmonary 
function tests. However, reduction in e.g. diffusion capacity 
varies widely between the grades of RP, making it less useful 
in routine clinical practice.  
To improve the quality of lung toxicity reporting 
investigations of Patient Reported Outcome (PRO) tools are 
being developed. In literature discrepancies between 
patients and clinicians reported toxicity as well as low 
correlation with CTCAE scoring are reported. Generally 
clinicians tend to underreport the incidence and severity of 
symptoms. In a recently published analysis of lung cancer 
patients treated with radiotherapy/chemoradiation 
agreement ranged from slight to substantial (ref 3). These 
differences underline the significance of the introduction of 
PROs in clinical trials. 
Summary: Dosimetric and clinical factors help us to estimate 
the incidence and severity of radiation induced pulmonary 
toxicity in clinical practice. In addition to these factors PROs 
tools on toxicity should be integrated in daily routine and in 
clinical trials to facilitate the doctors and patients decisions 
in the near future. 
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Radiotherapy (RT) plays a major role in the management of 
lung cancer as most patients are not surgical candidates due 
to stage, fitness and comorbidities. In the last decade we 
have witnessed tremendous changes in the role of radiation 
for the radical treatment of lung cancer as a result of the 
optimisation of chemo-radiotherapy combinations and 
technological advances. 
The technology available for RT planning, delivery and 
verification of lung cancer treatment is evolving at a fast 
pace. Unfortunately the evidence to demonstrate the benefit 
of such technology in terms of toxicity, local control, survival 
or quality of life is limited.  
Despite advances in the field of advanced RT techniques, 
local control with current RT doses delivered with standard 
3D conformal RT is poor with local progression-free survival 
rates of about 30 %, even with concurrent CTRT. It is now 
well accepted that that improved local control in lung cancer 
can lead to improvement in survival [Aupérin A. J Clin Oncol 
2010].   The following strategies can be combined to improve 
outcome in lung cancer include: 
•   Use of  Intensity-modulated radiotherapy 
IMRT is a  technique that adds fluence modulation to beam 
shaping, which improves radiotherapy dose conformity 
around the tumour and spares surrounding normal structures. 
Treatment with IMRT is becoming more widely available for 
the treatment of lung cancer, despite the paucity of high 
level evidence supporting the routine use of this more 
resource intense and complex technique [Chan. JTO 2014]. It 
allows the treatment of patients with large volume disease, 
close to critical organs at risk with curative doses. 
·          Dose escalation 
A clear radiation dose–response relationship exist in locally 
advanced NSCLC [Martel. Lung Cancer 1999]. The relationship 
between local control and BED is further suggested by data 
from SABR studies. The encouraging results of phase 1 and 2 
dose studies conducted in the 1990s formed the basis for the 
RTOG 0617 study [Bradley. ASCO 2013]. In that 2 x 2 factorial 
design study, patients with stage III NSCLC were randomized 
to receive high dose (74 Gy in 37 fractions) or standard dose 
(60 Gy in 30 fractions) RT concurrently with weekly 
paclitaxel/carboplatin with or without cetuximab. 
Disappointingly, there was a significant increase in the risk of 
death in the high-dose arms (median survival, 19.5 months vs 
28.7 months; p=0.0007), and a 37% increase in the risk of 
local failure in the high-dose arms (hazard ratio, 1.37; 
p=0.0319). There is therefore no role for dose escalation in 
stage III NSCLC using conventional dose fractionation 
·          Acceleration  
Hyperfractionated and/or accelerated fractionating 
schedules have demonstrated superior survival compared to 
conventional fractionation at the expense of greater 
oesophageal toxicity [Mauguen JCO 2012] 
·          Dose redistribution based on functional imaging 
Targeted dose escalation to tumour volumes resistant to 
treatment or at increased risk for recurrence is under 
evaluation [NCT01024829 and NCT01507428] 
•           Individualisation  of the dose (concept of isotoxic RT) 
The recognition of cancer heterogeneity has driven us away 
from the ‘one size fits all’ approach and has allowed tailoring 
of treatment to individualised patient-tumour characteristics. 
Isotoxic radiotherapy is a novel concept of personalised 
radiotherapy treatment allowing the individualised 
administration of radiotherapy dose based on predefined 
normal tissue constraints. 
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